- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
19
Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
Shuichiro Inatomi, Hiroshi Ohguro,
Nami Nishikiori, and Norimasa Sawada
CONTENTS
INTRODUCTION
STRUCTURAL AND FUNCTIONAL ASPECTS OF THE BLOOD-RETINAL
BARRIER (BRB)
MAJOR CYTOKINES DERIVED FROM GLIAL CELLS AFFECTING
TIGHT JUNCTIONS OF THE BRB
A POSSIBLE TREATMENT OF THE RETINOPATHY WITH RETINOIC
ACID ANALOGUES
CONCLUSION
REFERENCES
Keywords Blood retinal barrier • Inflammatory cytokines • Tight junctions • Retinoic acid
INTRODUCTION
Normal functions and environments of the retina are preferentially performed under homeostatic conditions which are exclusively maintained by the blood retinal barrier (BRB) [1, 2]. The BRB is composed of the inner BRB and the outer BRB. Endothelial cells of the retinal capillaries form the inner BRB, and pigment epithelial cells form the outer BRB. The structure of the inner BRB is considered to be analogous to that of the blood– brain barrier (BBB). The capillary endothelial cells of the BRB (hereafter, BRB is used to indicate the inner BRB) have highly impermeable tight junctions between endothelial cells composing the biological barrier, the most important cellular apparatus for the regulation of the paracellular passage [3]. In addition, the retinal capillaries are surrounded by end-feet of glial cells, similar to the BBB (Fig. 1A). It is believed that the glial cells have been supposed to enhance the barrier function of the BRB whose permeability is known to be regulated by glial cell–derived cytokines [4–6]. Thus, the retinal endothelial and glial cells form a functional unit of the biological barrier of the BRB to maintain retinal
From: Ophthalmology Research: Visual Dysfunction in Diabetes
Edited by: J. Tombran-Tink et al. (eds.), DOI 10.1007/978-1-60761-150-9_19 © Springer Science+Business Media, LLC 2012
325
326 |
Inatomi et al. |
Fig. 1. Schematic representation of TJ. (A) Left panel, in this structural model of TJ, there are a number of intercrossing TJ strands (depicted as small dots) and three so-called kissing points of TJ. Right panel, freeze-fracture replica of a TJ. The TJ consists of an anastomosing network of strands that form irregular interstrand compartments and is comprised of a large number of protein components, including membrane proteins such as occludin and claudins, as well as cytoplasmic scaffolding proteins such as ZO-1. Scale bar, 50 nm. (B) In polarized cells, TJs are positioned at the boundary of the apical and basolateral plasma membrane domains to maintain cell polarity by forming a fence. TJs also seal cells together to generate the primary barrier and prevent diffusion of solutes through the paracellular pathway. In addition, a certain type of TJ protein such as occludin is a signaling molecule that has functions in receiving environmental cues and transmitting signals inside the cells.
homeostatic conditions, and this is often destroyed under pathological conditions, such as diabetic retinopathy [7, 8], uveitis [9], and other ocular inflammation and ischemia [10].
In diabetic retinopathy, microvascular complications such as macular edema and retinal neovascularization cause adult blindness of patients with diabetes mellitus [11]. During the pathological progression of diabetic retinopathy, leukocyte binding to the retinal vascular endothelium detected as an initial event results in early BRB breakdown, capillary nonperfusion, and endothelial cell death [12–15]. Also possible are molecular events within the initial stage of the diabetic retinopathy, an increase of vascular permeability caused by the breakdown of BRB, and upregulation of several cytokines and intracellular adhesion molecules. These pathological events merge to contribute to the development of retinal ischemia, diabetic macular edema, and neovascularization. In fact, during this pathological progression of the diabetic retinopathy, several intracellular adhesion molecules, including sICAM-1 and sVCAM-1 [16, 17], and inflammatory cytokines, including TNF-a and IL-1b [18, 19], VEGF [17, 20], GDNF [21, 22], and IL-6 [23], and
Glial Cell–Derived Cytokines and Vascular Integrity |
327 |
others, are induced by high levels of glucose in vitro and in vivo, and high concentrations of these mediators are detected in vitreous or plasma specimens from patients with diabetic retinopathy. Based upon the release profiles of these mediators from pericytes, it was speculated that TNF-a and IL-1b are initially released and trigger the release of intercellular adhesion molecule-1 (ICAM-1) and sVCAM-1, which affect leukostasis, and VEGF, GDNF, and IL-6, which induce vascular permeability during the initial stage of the diabetic retinopathy [24].
In this chapter, to get a better understanding of the pathophysiological roles of glial cell–derived cytokines in the diabetic retinopathy, we focus on the structural and functional aspects of the BRB and its modulation by cytokines derived from glial cells under pathological conditions at an early phase of diabetic retinopathy. In addition, we also describe the possible treatment and prevention of the retinopathy with retinoic acid analogue that affects the glial cell–derived cytokines.
STRUCTURAL AND FUNCTIONAL ASPECTS
OF THE BLOOD-RETINAL BARRIER (BRB)
The BRB Functional Unit Composed of Glial and Endothelial Cells
The endothelial cells of the BRB form near continuous sheets because of impermeable tight junctions (Fig. 1B). They also show no fenestration and few pinocytic vesicles. These distinctive features of the BRB-forming endothelial cells from capillary endothelial cells in other tissues maintain unique microenvironment essential for functions of retinal cells. Thus the tight junction of the BRB-forming endothelial cells is a substantial barrier that strictly regulates the paracellular pathways between the cells. Another unique feature of the endothelial cells that form the BRB and the BBB is that the capillaries forming the barrier are almost all ensheathed by vascular feet of astrocytes [25]. The anatomical relationship between the endothelial cells and astrocytes has prompted some of the researchers to explore a functional relationship between these cells. In fact, the characteristics of endothelial cells of the BBB are induced using chick-quail transplantation.
The transplantation of astrocytes into the avascular space of the anterior eye chamber showed that the capillaries that invaded the chamber were similar in characteristics to the BBB-forming endothelial cells. In vitro, a combination of an astrocyte-conditioned medium and cAMP made a tight junction resistant to the paracellular passage [26–28]. Since paracellular passage between the endothelial cells, mostly provided by the structural organization of tight junctions, astrocytes are strongly suggested to secrete some mediators that regulate paracellular passage, in terms of regulation of the tight junctions between the endothelial cells [29]. These findings strongly suggest an important insight into the permeability of the BBB between endothelial cells and astrocytes. In other words, it is feasible that astrocytes regulate the barrier function of the BRB, in terms of impermeability, in a paracrine manner.
Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
Tight junctions, the most apical component of intercellular junctional complexes, separate the apex from the basolateral cell surface domains to establish cell polarity (performing the function of a fence) [26–29] (Fig. 2). Tight junctions also possess a barrier function, inhibiting the flow of solutes and water through the paracellular space [26–29].
328 |
Inatomi et al. |
Fig. 2. Glial cell as a main component of BRB. (A) Schematic presentation of BRB. Note that cytoplasm of glial cell associates both with neural cell and capillary endothelium (open circles). (B) BRB is a biological unit comprised of specialized endothelial cells firmly connected by intercellular TJs and the endothelium-surrounding glial cells. Glial cell–derived cytokines such as VEGF and GDNF closely associate with the vascular integrity, which is regulated by modulating the TJ function of capillary endothelium in a paracrine manner. (C) BRB-forming glial cell expresses GDNF in the murine retina. Glial cell is highlighted by red in the retina, which is stained with anti-GFAP, a specific marker for glial cell in central nervous system and retina (a, left panel). GDNF expression shows similar distribution in green, suggesting that glial cell expresses GDNF protein (B, right panel).
They form a particular netlike meshwork of fibrils created by the integral membrane proteins, occludin and claudin, and members of the Ig superfamilies JAM and CAR [30]. Several peripheral membrane proteins related to tight junctions, such as ZO-1, ZO-2, ZO-3, 7H6 antigen, cingulin, symplekin, Rab3B, Ras target AF-6, and ASIP, an atypical protein kinase C-interacting protein, have been reported [3, 25, 31]. Recently, a new integral membrane protein tricellulin was also identified at tricellular contacts, which consist of three epithelial cells and have a barrier function [32].
